Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Technical Presentation (September 2025)
26 slides from Revelation Biosciences's technical presentation, Sep 9, 2025
Slide 1: PRIME Phase 1b Top-line Data Review
PRIME Phase 1b Top-line Data Review NASDAQ: REVB www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the
Slide 3: Gemini Platform
Gemini Platform Program Therapeutic Indication Discovery Phase 1 Phase 2 Phase 3 GEM-AKI Acute Kidney Injury GEM-CKD Chronic Kidney Disease GEM-PSI Post Surgical Infection GEM-PBI Post Burn Infection Portfolio Multiple2 1 Gemini is our proprietary formulation platform intended to optimize PHAD’s rou
Slide 4: Key Study Findings
Key Study Findings • Primary safety endpoint met – no serious or severe adverse events up to target dose • Gemini significantly reduced background inflammation to normal levels and restored normal cell response to stimuli in peripheral blood mononuclear cells (PBMCs) demonstrating rebalancing of imm
Slide 5: PRIME – PRotective IMmunostimulatory Evaluation
PRIME – PRotective IMmunostimulatory Evaluation A Phase 1b, Randomized, Placebo Controlled, Single Blind, Single-Ascending Dose in Stage 3 and Stage 4 CKD Patients Design • Single dose, dose escalation • 5 cohorts, 8 subjects per cohort 1:4 placebo vs drug (up to 40 patients) • Cohort 1 – Subtherape
Slide 6: Peripheral Blood Mononuclear Cell (PBMC) Methodology
Peripheral Blood Mononuclear Cell (PBMC) Methodology Evaluation of PBMCs collected at different time points post-dose provide a picture of the in vivo effect of Gemini at the cellular level over time Subjects administered Gemini or Collect whole Placebo blood Blood sample collected at Predose and 2,
Slide 7: Patients were Divided into Two Groups for Analysis
Patients were Divided into Two Groups for Analysis • Patient PBMCs with a high background of inflammation (IL-1) at predose: all patients with >10x the limit of quantitation for IL-1 (>40 pg/mL) at predose • PBMCs with high background inflammation do not respond to stimulation with LPS or HMGB- 1
Slide 8: Effect of Gemini on Patient PBMCs with High Background Inflammation
Effect of Gemini on Patient PBMCs with High Background Inflammation 8
Slide 9: % IL-1 relative to baseline
Gemini significantly reduces IL-1 production compared to placebo 200% Change in IL-1 at 2 hours 1 180% 160% % IL-1 relative to baseline P<0.01 140% 120% 120% 100% 100% 80% 80% 60% 60% * 40% 40% * 20% 20% 0% 0% 0 50 100 150 200 Placebo Target dose Hour Placebo Target dose 1p value based on 2-taile
Slide 10: % TNF-α relative to baseline
Gemini significantly reduces TNF- production compared to placebo 120% Change in TNF- at 2 hours 1 % TNF-⍺ relative to baseline 100% P=0.01 80% 140% 120% 60% * * 100% 40% 80% 60% 20% 40% 20% 0% 0% 0 50 100 150 200 Hour Placebo Target dose Placebo Target dose 1p value based on 2-tailed t-test *Reduc
Slide 11: % IL-6 relative to baseline
Gemini significantly reduces IL-6 production compared to placebo 120% Change in IL-6 at 2 hours1 100% % IL-6 relative to baseline P<0.01 160% 80% 140% 120% 60% 100% * 80% 40% 60% * 40% 20% 20% 0% 0% 0 50 100 150 200 Placebo Target dose Hour Placebo Target dose 1p value based on 2-tailed t-test *Redu
Slide 12: % IL-10 relative to baseline
Gemini significantly reduces IL-10 production compared to placebo 140% Change in IL-10 at 2 hours1 120% % IL-10 relative to baseline P<0.01 100% 250.0% 200.0% 80% * 150.0% 60% 100.0% 40% * 50.0% 20% 0.0% 0% Placebo Target dose 0 50 100 150 200 Hour Placebo Target dose 1p value based on 2-tailed t-te
Slide 13: % IL-1RA relative to baseline
Gemini significantly reduces IL-1RA production compared to placebo 140% Change in IL1RA at 2 hours 1 120% % IL-1RA relative to baseline P<0.001 100% 250% 80% 200% * 150% 60% * 100% 40% 50% 20% 0% 0% Placebo Target dose 0 20 40 60 80 100 120 140 160 180 Hour Placebo Target dose 1p value based on 2-ta
Slide 14: % IL-1 Relative to Predose
Gemini restored normal1 PBMC IL-1 response to LPS stimulation 7000% Change in IL-1 response to LPS at all timepoints post dose 6000% % IL-1 Relative to Predose 5000% P<0.0001 2 4000% 18000% 16000% 3000% 14000% 12000% 2000% 10000% 8000% 1000% 6000% 4000% 0% 2000% 0 50 100 150 200 0% Hour Placebo T
Slide 15: % IL-6 Relative to Predose
Gemini restored normal1 PBMC IL-6 response to LPS stimulation 12000% Change in IL-6 response to LPS at all timepoints post dose 10000% % IL-6 Relative to Predose 8000% P<0.00022 30000% 6000% 25000% 20000% 4000% 15000% 2000% 10000% 5000% 0% 0% 0 50 100 150 200 Hour Placebo Target Dose Placebo Target
Slide 16: % TNF-α Relative to Predose
Gemini restored normal1 PBMC TNF- response to LPS stimulation 4500% 4000% Change in TNF- response to % TNF- Relative to Predose LPS all time points post dose 3500% 3000% P<0.0022 2500% 12000% 2000% 10000% 1500% 8000% 6000% 1000% 4000% 500% 2000% 0% 0 50 100 150 200 0% Hour Placebo Target dose Pla
Slide 17: % IL-1RA Relative to Predose
Gemini restored normal1 PBMC IL-1RA response to LPS stimulation 200% Change in IL-1RA response to LPS 180% at all timepoints post dose % IL-1RA Relative to Predose 160% P<0.012 140% 120% 350% 300% 100% 250% 80% 200% 60% 150% 40% 100% 20% 50% 0% 0% 0 50 100 150 200 Placebo Target Dose Hour Placebo Ta
Slide 18: % IL-10 Relative to Predose
Gemini restored normal1 PBMC IL-10 response to LPS stimulation 2500% 2000% % IL-10 Relative to Predose Change in IL-10 response to LPS at all time points post dose 1500% 4000% NS2 3500% 1000% 3000% 2500% 500% 2000% 1500% 1000% 0% 500% 0 50 100 150 200 0% Hour Placebo Target dose Placebo Target dose
Slide 19: Comparable results were observed for HMGB-1 stimulation
Comparable results were observed for HMGB-1 stimulation P<0.05* P<0.05* 800% 300% 600% 400% % IL-1 relative to % IL-10 relative to 600% 250% 400% 200% 300% 400% 200% baseline baseline 200% 150% 200% 0% 100% 0% 50% 0 200 100% 0 100 200 0% Hour 0% Hour Placebo Target dose Placebo Target Dose Placebo
Slide 20: Effect of Gemini on Patient PBMCs with Low Background Inflammation
Effect of Gemini on Patient PBMCs with Low Background Inflammation 20
Slide 21: Gemini does not increase inflammatory activity in low background patients
As expected, Gemini does not increase inflammatory activity in low background patients 1 1p value based on 2-tailed t-test 21
Slide 22: Safety Summary
Safety Summary /\ REVELATION
Slide 23: RVL-CKD01 Treatment Emergent Adverse Events
RVL-CKD01 Treatment Emergent Adverse Events Number of Total Events by Severity Gemini Gemini Gemini Gemini Subtherapeutic dose Low dose Target dose High dose Placebo Overall N=6 N=8 N=12 N=6 N=8 N = 40 Mild (Grade I) 3 2 8 2 – 15 Moderate (Grade II) – 3 4 2 1 10 Severe (Grade III) – – – 3 – 3 Life-T
Slide 24: RVL-CKD01 Treatment Emergent Adverse Events Related to Gemini
RVL-CKD01 Treatment Emergent Adverse Events Related to Gemini Adverse Event Number of Events Grade Subtherapeutic dose Headache/Head Pain 1 Mild (Grade I) Headache/Head Pain 1 (Moderate (Grade II) Low dose Dizziness 1 (Moderate (Grade II) Nausea 1 Mild (Grade I) Headache/Head Pain 2 Mild (Grade I) C
Slide 25: Key Takeaways
Key Takeaways • Gemini corrects high background inflammation in patient PBMCs o High background PBMCs from untreated patients do not respond to stimulation (a form of immunoparalysis) o Gemini restores normal cell responsiveness to stimulation o The rebalancing effect is durable (out to one week pos
Slide 26: Thank You!
Thank You! For more information, please visit www.revbiosciences.com 26
Revelation Biosciences — Technical Presentation (September 2025) on 6ix